Inogen (NASDAQ:INGN – Get Free Report) issued its quarterly earnings results on Thursday. The medical technology company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.42), Zacks reports. The business had revenue of $77.19 million during the quarter, compared to analysts’ expectations of $92.25 million. Inogen had a negative return on equity of 19.29% and a negative net margin of 10.46%.
Here are the key takeaways from Inogen’s conference call:
- Third-quarter revenue from continuing operations was $77.2 million, down 2.4% year over year. U.S. sales grew 3.8%, but international sales fell 9% amid weaker European customer spending, a trend Inogen expects to continue into the fourth quarter.
- U.S. sales returned to year-over-year growth for the first time since late 2024, supported by distributor demand and new products. Portable oxygen concentrator unit volume increased nearly 6%, with new products contributing about 250 basis points of growth.
- Inogen completed the U.S. oxygen rental divestiture, with estimated cash consideration of up to $24.8 million expected in the first half of 2027. The company also announced a cost-reduction program targeting $20 million in annualized savings by the end of 2027; combined with the divestiture, savings are expected to exceed $40 million versus the pre-divestiture run rate.
- GAAP loss from continuing operations was $14.8 million, including a $10.6 million non-cash goodwill impairment, and operating cash flow was negative $4.5 million. Inogen expects a full-year adjusted net loss of $7 million to $8 million and fourth-quarter revenue of $65 million to $68 million.
- The company ended the quarter with $97.7 million in cash, cash equivalents, marketable securities, and restricted cash, with no debt outstanding. It increased its share repurchase authorization by $15 million to a total of $45 million.
Inogen Trading Up 1.4%
Shares of NASDAQ:INGN traded up $0.08 during midday trading on Monday, reaching $6.11. 289,827 shares of the company were exchanged, compared to its average volume of 298,131. The business’s fifty day moving average is $5.96 and its two-hundred day moving average is $6.23. Inogen has a one year low of $5.05 and a one year high of $7.67. The stock has a market cap of $162.24 million, a PE ratio of -4.67 and a beta of 1.51.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inogen in a research note on Tuesday, November 3rd. One research analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy”.
Check Out Our Latest Stock Analysis on INGN
About Inogen
Inogen, Inc is a medical technology company that develops, manufactures and markets portable oxygen concentrators for people who require long-term supplemental oxygen therapy. Its devices separate oxygen from ambient air and deliver concentrated oxygen without the need for traditional compressed-gas or liquid-oxygen tanks.
The company’s product portfolio has included the Inogen One portable oxygen concentrator line, as well as stationary and related oxygen therapy products. These systems are designed to support mobility and independence for patients with chronic respiratory conditions while offering features such as rechargeable batteries, portability and various oxygen-delivery settings.
Founded in 2001 and headquartered in Goleta, California, Inogen sells its products through direct-to-consumer channels, health-care providers, distributors and other commercial partners.
Featured Articles
- Five stocks we like better than Inogen
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.
